A Phase 1/2 Clinical Trial to Assess Safety and Efficacy of a New Treatment for Hodgkin Lymphoma's Disease Combining Adcetris and Levact in Old Patients

Trial Profile

A Phase 1/2 Clinical Trial to Assess Safety and Efficacy of a New Treatment for Hodgkin Lymphoma's Disease Combining Adcetris and Levact in Old Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HALO
  • Most Recent Events

    • 21 Feb 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 21 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 06 Dec 2016 Preliminary results (n=14) assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top